NasdaqGM - Nasdaq Real Time Price USD

Atai Life Sciences N.V. (ATAI)

2.3100

-0.0100

(-0.43%)

At close: May 30 at 4:00:02 PM EDT

2.3000

-0.01

(-0.43%)

After hours: May 30 at 7:55:18 PM EDT

atai Life Sciences to Participate in Upcoming Investor Conferences

NEW YORK and BERLIN, May 29, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, today announced that the Company’s management team is scheduled to participate in the following investor conferences in June: Jefferies Global Healthcare Conference Format: Fireside ChatDate and Time: Thursday, June 5 at 9:55 A.M. EDTLocation: New Y

GlobeNewswire yesterday

ATAI
-0.43%
Phase 2a data for BPL-003 ‘encouraging’ for Atai Life Sciences, says Jefferies

Jefferies analyst Andrew Tsai notes that Beckley Psytech shared positive Phase 2a data on BPL-003 in combination with SSRI antidepressants for treatment-resistant depression that the firm calls “encouraging.” The drug’s profile seems to be consistent across multiple studies, incrementally de-risking the key Phase 2b TRD study in mid-2025, the analyst tells investors. Although the BPL-003 program is controlled by Beckley Psytech, Atai Life Sciences (ATAI) currently holds about a 34% stake in Beck

TipRanks 9 days ago

ATAI
-0.43%
Home Depot backs outlook as U.S. sales ticked up: Morning Buzz

Stocks are lower at midday, putting in jeopardy the six-day winning streak for the S&P 500. Federal Reserve officials’ commentary is anticipated to provide insights into the central bank’s outlook on inflation and interest rates, while markets continue digesting the implications of Moody’s recent downgrade of the U.S. sovereign credit rating, which has heightened concerns about the nation’s fiscal health as lawmakers debate President Trump’s “big, beautiful” tax bill. Looking ahead, investors ar

TipRanks 9 days ago

TCOM

TRPCF

MSFT
atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech’s Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression

- Positive results show that a single dose of BPL-003, administered adjunctively to SSRIs, produced a rapid and durable antidepressant effect for up to three months after dosing - BPL-003 was well-tolerated and patients were able to be discharged within an average time of less than two hours after dosing - Data from the eight-week core, randomized stage of Beckley Psytech’s Phase 2b study of BPL-003 for treatment-resistant depression is expected in mid-2025 NEW YORK and BERLIN, May 20, 2025 (GLO

GlobeNewswire 10 days ago

ATAI
-0.43%
atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates

With clinical momentum across its pipeline, atai strengthens its position as a leader in potentially transformative psychedelic mental health treatments Anticipate topline data midyear from the Phase 2b clinical trial of BPL-003 in patients with treatment-resistant depression (TRD) - the largest controlled trial of mebufotenin and the first and only such trial to investigate mebufotenin in the U.S.Dosed the first patient in the exploratory Phase 2 study of EMP-01 (oral R-MDMA) for the treatment

GlobeNewswire 16 days ago

ATAI
-0.43%
atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder

- In a Phase 1 study, EMP-01 (oral R-MDMA) demonstrated a unique, dose-dependent subjective effect profile that was generally found to be more similar to classical psychedelics than to racemic MDMA - The exploratory, randomized, double-blind, placebo-controlled Phase 2 study will assess the safety, tolerability and efficacy of EMP-01 in adults with social anxiety disorder - Topline data anticipated in the first quarter of 2026 NEW YORK and BERLIN, May 13, 2025 (GLOBE NEWSWIRE) -- atai Life Scien

GlobeNewswire 17 days ago

ATAI
-0.43%
Psychedelic: Clearmind initiates U.S. clinical site for CMND-100 trial

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a clinical site initiation, an FDA authorization and an analyst initiation. CLEARMIND INITIATES U.S. SITE FOR CMND-100 TRIAL: Clearmind Medicine (CMND) announced Thursday that it has initiated its Phase I/IIa clinical trial at its first U.S. clinical site, the Johns Hopkins University School of Medicine. The first-in-human clinical trial will investigate the safety, tolerability and

TipRanks last month

RVVTF

AGNPF

ATAI
-0.43%
Psychedelic: Exclusive talk with biotech company Clearmind Medicine

In this edition of “Psychedelic”, The Fly conducted an exclusive interview with Mark Haden, vice president of business development at Clearmind Medicine (CMND), a psychedelic pharmaceutical biotech company focused on development of therapeutics to solve underserved health problems. Here are some highlights: PSYCHEDELIC PHARMA: Clearmind is a clinical-stage biotech company that aims to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods

TipRanks 2 months ago

CMND

ATAI
-0.43%

GHRS
Psychedelic: atai Life Sciences, NRx report quarterly results

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, a collaboration LOI and a study publication. EARNINGS: On Monday, atai Life Sciences (ATAI) reported a fourth quarter loss per share of (24c) on revenue loss of ($5,000), which compared to analyst estimates of a loss per share of (15c) and revenue of $18,000 for the same period last year. As of December 31, the company had cash, cash equivalents, restricted cash and short-t

TipRanks 2 months ago

CYBN

ATAI
-0.43%

CMND
Atai Life Sciences Full Year 2024 Earnings: Misses Expectations

Atai Life Sciences ( NASDAQ:ATAI ) Full Year 2024 Results Key Financial Results Net loss: US$149.3m (loss widened by...

Simply Wall St. 2 months ago

ATAI
-0.43%
atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

- Dosed the first patient in the Phase 2 Elumina trial of VLS-01 (buccal film DMT) for patients with treatment-resistant depression; topline data anticipated in Q1’26 - Initiated a Phase 2 clinical trial of EMP-01 (oral R-MDMA) for patients with social anxiety disorder; topline data anticipated in Q1’26 - Beckley Psytech completed enrollment in the Phase 2b study of BPL-003 (intranasal mebufotenin benzoate) in patients with treatment-resistant depression; topline data anticipated in mid-25 - Com

GlobeNewswire 2 months ago

ATAI
-0.43%
Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a dosing initiation, a development expansion and a distribution agreement. ATAI DOSES FIRST PATIENT IN PHASE 2 VLS-01 TRIAL: atai Life Sciences (ATAI) announced Tuesday that the first patient has been dosed in the Phase 2 Elumina trial of VLS-01, atai’s proprietary oral transmucosal film formulation of N,N-Dimethyltryptamine applied to the buccal surface, in people suffering from tre

TipRanks 2 months ago

ATAI
-0.43%

MNMD

CMND
atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression

- Elumina is a Phase 2, multicenter, double-blind, randomized, placebo-controlled, clinical trial to assess the efficacy, safety and tolerability of VLS-01 (buccal film DMT) in people suffering from treatment-resistant depression - VLS-01 is being developed as a rapid-acting, robust and durable antidepressant for people suffering from treatment-resistant depression, which affects approximately 100 million people globally - VLS-01 is designed to fit within the established two-hour interventional

GlobeNewswire 2 months ago

ATAI
-0.43%
atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression

- The eight-week, quadruple-masked, dose-finding, core stage of the Phase 2b clinical trial is evaluating the efficacy and safety of a single dose of BPL-003 (mebufotenin benzoate) in patients with treatment-resistant depression - The open-label extension stage of the Phase 2b clinical trial continues to enroll patients to evaluate the safety and efficacy of a second dose of BPL-003 - As previously reported, the Phase 2a study of BPL-003 in patients with treatment-resistant depression showed rap

GlobeNewswire 2 months ago

ATAI
-0.43%
Atai Life Sciences N.V. (ATAI): Among the Best Psychedelic Stocks to Buy in 2025

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at where Atai Life Sciences N.V. (NASDAQ:ATAI) stands against the other psychedelic stocks. The Therapeutic Potential and Investment Boom in Psychedelic Medicine In contrast to drugs like cocaine or marijuana, psychedelics […]

Insider Monkey 2 months ago

ATAI
-0.43%
Psychedelic: GH Research, Compass Pathways report earnings results

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, an analyst initiation and patent issuance. EARNINGS: On Thursday, GH Research (GHRS) reported a FY24 loss per share of (75c), which compared to analyst estimates of loss per share of (80c). The company also reported cash, cash equivalents, other financial assets and marketable securities at $182.6M as of December 31, compared to cash, cash equivalents, other financial asset

TipRanks 2 months ago

QNTM

ENVB

CYBN
atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference

NEW YORK and BERLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s management team is scheduled to participate in the TD Cowen 45th Annual Health Care Conference in Boston, MA from March 3-5, 2025. Details of the company’s participation: Format: Fireside chat and 1x1 investor meetingsDate and Time: Fireside chat o

GlobeNewswire 3 months ago

ATAI
-0.43%
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares

NEW YORK and BERLIN, Feb. 20, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced that, on February 14, 2025, the closing of its public offering of 26,190,477 common shares occurred. Additionally, on February 17, 2025, the underwriter exercised its option in full to purchase an additional 3,928,571 common shares at the public offering price of

GlobeNewswire 3 months ago

ATAI
-0.43%
atai Life Sciences Announces Pricing of Public Offering of Common Shares

NEW YORK and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the pricing of a registered underwritten offering of 26,190,477 common shares, at a price of $2.10 per share. atai has granted the underwriter a 30-day option to purchase up to an additional 3,928,571 common shares. All common shares to be sold in the offering wi

GlobeNewswire 3 months ago

ATAI
-0.43%
atai Life Sciences Announces Proposed Public Offering of Common Shares

NEW YORK and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the commencement of a proposed registered underwritten offering of $55,000,000 of its common shares. atai expects to grant the underwriter a 30-day option to purchase up to an additional $8,250,000 of common shares. All common shares to be sold in the offering wi

GlobeNewswire 3 months ago

ATAI
-0.43%

Performance Overview

Return	ATAI	S&P 500 (^GSPC)
YTD	+73.68%	+0.51%
1-Year	+37.50%	+12.92%
3-Year	-43.24%	+42.17%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Atai Life Sciences N.V. (ATAI)

atai Life Sciences to Participate in Upcoming Investor Conferences

Phase 2a data for BPL-003 ‘encouraging’ for Atai Life Sciences, says Jefferies

Home Depot backs outlook as U.S. sales ticked up: Morning Buzz

atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech’s Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression

atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates

atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder

Psychedelic: Clearmind initiates U.S. clinical site for CMND-100 trial

Psychedelic: Exclusive talk with biotech company Clearmind Medicine

Psychedelic: atai Life Sciences, NRx report quarterly results

Atai Life Sciences Full Year 2024 Earnings: Misses Expectations

atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial

atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression

atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression

Atai Life Sciences N.V. (ATAI): Among the Best Psychedelic Stocks to Buy in 2025

Psychedelic: GH Research, Compass Pathways report earnings results

atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference

atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares

atai Life Sciences Announces Pricing of Public Offering of Common Shares

atai Life Sciences Announces Proposed Public Offering of Common Shares

Performance Overview